21461-85-8

Basic information

• Product Name: (S)-methyl 5-oxotetrahydrofuran-2-carboxylate
• Synonyms: (S)-methyl 5-oxotetrahydrofuran-2-carboxylate
• CAS NO: 21461-85-8
• Molecular Formula: C₆H₈O₄
• Molecular Weight: 144.12532
• Mol File: 21461-85-8.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (S)-methyl 5-oxotetrahydrofuran-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-methyl 5-oxotetrahydrofuran-2-carboxylate(21461-85-8)
• EPA Substance Registry System: (S)-methyl 5-oxotetrahydrofuran-2-carboxylate(21461-85-8)

Safety Data

• Hazardous Substances Data: 21461-85-8(Hazardous Substances Data)

Usage

Description

(S)-methyl 5-oxotetrahydrofuran-2-carboxylate is a chiral chemical compound with the molecular formula C6H8O4. It is a derivative of tetrahydrofuran and is characterized by its specific stereochemistry. (S)-methyl 5-oxotetrahydrofuran-2-carboxylate is commonly utilized in organic synthesis and has demonstrated potential biological activities, making it a promising candidate for pharmaceutical research and development. Furthermore, it serves as a reference standard in analytical chemistry for identifying and quantifying similar compounds in various samples.

Uses

Used in Organic Synthesis:
(S)-methyl 5-oxotetrahydrofuran-2-carboxylate is used as a building block in the synthesis of various pharmaceuticals and natural products. Its unique structure and reactivity make it a valuable component in creating complex organic molecules.
Used in Pharmaceutical Research and Development:
As a chiral molecule with potential biological activities, (S)-methyl 5-oxotetrahydrofuran-2-carboxylate is used in pharmaceutical research and development. It is studied for its potential as a drug candidate, offering new avenues for the treatment of various diseases and conditions.
Used in Analytical Chemistry:
(S)-methyl 5-oxotetrahydrofuran-2-carboxylate is used as a reference standard in analytical chemistry. It aids in the identification and quantification of similar compounds in a range of samples, ensuring accurate and reliable results in chemical analysis.

Upstream product

• 186581-53-3 diazomethane 
• 21461-84-7 (2S)-tetrahydro-5-oxofuran-2-carboxylic acid 
• 13192-04-6 dimethyl 2-ketoglutarate 
• 3885-29-8 (+/-)-tetrahydro-5-oxo-2-furancarboxylic acid methyl ester 
• 67-56-1 methanol 
• 328-50-7 α-ketoglutaric acid 
• 81077-10-3 methyl 2-hydroxy-4-(metoxycarbonyl)butanoate 
• 56-86-0 L-glutamic acid 

Downstream Products

• 1126-51-8 (S)-(+)-tetrahydro-5-oxo-2-furancarboxylic acid ethyl ester 
• 239125-39-4 5-methyl (3R,5S)-3-acetylamino-2-oxotetrahydrofuran-5-carboxylate 
• 239125-39-4 5-methyl (3S,5S)-3-acetylamino-2-oxotetrahydrofuran-5-carboxylate 

Relevant articles and documents

A new synthesis of alkaloid (S)-3-hydroxypiperidin-2-one and its O-TBS protected derivative

(Chemical Equation Presented) From the known lactone (S)-4, easily derived from L-glutamic acid, a scalable approach to chiral building block O-silylated 3-hydroxypiperidin-2-one 3 and alkaloid 1 was achieved in five and six-steps respectively. The key st

MODULATORS OF G-PROTEIN COUPLED RECEPTORS

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize or partially agonize or antagonize) glucagon?like peptide?1 receptor ("GLP?1R") and/or the gastric inhibitory polypeptide receptor ("GIPR"). The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP?1R and/or GIPR activities is benficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, the modulation results in an enhancment of (e.g., an increase in) existing levels (e.g., normal or below normal levels) of GLP?1R and/or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple) -arrestin signaling relative to what is observed with the native ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.

Combination strategy using pure enzymes and whole cells as biocatalysts for the preparation of 2-hydroxyesters and lactones from 2-oxoglutaric acid

An innovative combination strategy that uses pure enzymes and whole microbial cells in the same process was used to prepare enantiomerically pure 3-carboxyalkyl-γ-butyrolactones and several alkyl esters of 2-hydroxyglutarate from 2-oxoglutaric acid. An innovative combination strategy that uses pure enzymes and whole microbial cells in the same process was used to prepare enantiomerically pure 3-carboxyalkyl-γ-butyrolactones and several alkyl esters of 2-hydroxyglutarates from 2-oxoglutaric acid. The method involves two consecutive biocatalytic steps. The first step, which converts the 2-oxoglutaric acid into the corresponding dialkyl esters, was catalyzed by a lipase. Then in the second step, by microbial reduction of the dialkyl-2-oxoglutarates, it is possible to obtain 3-carboxyalkyl-γ- butyrolactones or 2-hydroxyesters depending on the length of the chain in the alkyl moiety of the esters and on the fresh or lyophilized status of the cells.